Advantage Alpha Capital Partners LP Raises Holdings in Enovis Co. (NYSE:ENOV)

Advantage Alpha Capital Partners LP boosted its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 49.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 87,955 shares of the company's stock after buying an additional 29,139 shares during the period. Advantage Alpha Capital Partners LP owned 0.16% of Enovis worth $3,786,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company grew its position in shares of Enovis by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 66,668 shares of the company's stock worth $2,870,000 after purchasing an additional 2,123 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Enovis in the 3rd quarter worth approximately $1,050,000. Charles Schwab Investment Management Inc. grew its holdings in Enovis by 14.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 600,819 shares of the company's stock valued at $25,865,000 after buying an additional 73,623 shares in the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Enovis during the third quarter valued at approximately $331,000. Finally, Quest Partners LLC purchased a new position in shares of Enovis in the third quarter worth $741,000. 98.45% of the stock is owned by institutional investors.

Enovis Trading Down 1.1 %

ENOV stock traded down $0.53 during mid-day trading on Tuesday, reaching $47.74. The company had a trading volume of 779,791 shares, compared to its average volume of 582,953. The firm has a 50 day moving average of $42.81 and a 200 day moving average of $44.90. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a market capitalization of $2.67 billion, a PE ratio of -22.04 and a beta of 1.91.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. During the same period last year, the business posted $0.56 EPS. Enovis's quarterly revenue was up 21.0% on a year-over-year basis. On average, equities analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ENOV has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Evercore ISI decreased their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. JMP Securities assumed coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.